Ketogenic diet therapy for high-grade gliomas combined with standard treatment using an angiogenesis inhibitor: An exploratory pilot study on feasibility.

ABSTRACT:

Background

Altered tumor metabolism has renewed interest in ketogenic strategies, despite limited clinical evidence in glioma. Whereas the ketogenic diet (KD) alone elevates intratumoral amino acids, bevacizumab (BEV) co-administration suppresses these metabolites and curtails tumor growth, pointing to a synergistic therapeutic potential.

Methods

We conducted a clinical pilot study to evaluate the combination of KD and standard therapy, combining BEV, in patients with malignant glioma. A standardized modified ketogenic diet (mKD) regimen was implemented: carbohydrate intake was restricted to 10 g/day in the first week, 20 g/day in the following 2 months, and ≤30 g/day thereafter. MCT oil was administered at ≥50 mL/day, and ketone formula supplements were provided as needed.

SUBMITTER: Sasayama T 

PROVIDER: S-EPMC12924638 | biostudies-literature | 2026 Jan-Dec

REPOSITORIES: biostudies-literature